Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.


17 04, 2013

What took so long? Pomalidomide time-line raises questions–I have answers (Part Three)

Tags: , , , , , , , , , |5 Comments

I stuck with the original heading for the third installment of my three part investigative expose'.  But today's post could have been titled, "Different shades of grey."   Pomalidomide's development was shaped by a convoluted system that does a poor job balancing patient need with investor returns. But I'm getting ahead of myself.  Yesterday I promised

19 03, 2013

Responding to IMiD and proteasome inhibitor may be game changer

Tags: , , , , , , , , , , |18 Comments

Friday I left everyone hanging when I wrote:  Monday I am going to explain how this seemingly mundane result–a 0.2 M-spike–may have been the most fateful news I have ever received as a soon to be six year multiple myeloma survivor.  I know I said Monday.  But I couldn't resist yesterday's fun and frivolous, self

25 09, 2012

Is it “all about the money?” Depends how you spin it…

Tags: , , , , |4 Comments

In case you missed it, the U.S. Food and Drug Administration has set a date for an advisory committee meeting to review the company’s application for approval of pomalidomide:  November 8th of this year. The agency is expected to make a decision about pomalidomide’s (New trade name, Actimid) application sometime early in February, 2013. Pomalidomide

11 12, 2009

How Does Thalomid, Revlimid or Pomalidomide Work?

Tags: , , , , |0 Comments

I wanted to follow-up my previous post for those of you who are more scientifically and technically minded with a summary conclusion from an even more complicated study I found this afternoon:Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, Prince HM.[1] Department